You know that scene in Batman: The Dark Knight where the Joker burns a mountain of cash and says "it's not about the money, it's about sending a message"?
Yeah. Vinay Prasad just left the building. And the mountain of money he burned was the pharmaceutical industry's trust in the American regulatory process.
The guy who walked in to wreck the place
Prasad was the director of the Center for Biologics Evaluation and Research (CBER) — the arm of the FDA that oversees vaccines and biological treatments. In plain English: the guy who decides whether the vaccine you take or the biotech drug that could save your life makes it to market or dies in bureaucratic limbo.
On Friday, the FDA confirmed he's out at the end of April. Spicy detail: this is the second time he's leaving the job. In July, he walked out under a hailstorm of criticism. He came back two weeks later, in August, like nothing ever happened. Like that employee who rage-quits on Friday and shows up Monday morning with his badge around his neck.
FDA Commissioner Marty Makary dropped a post on X saying Prasad "accomplished a tremendous amount" during his tenure. Translation from diplomatic bureaucratese: "the guy made a hell of a lot of noise and now we need to clean up the mess."
What did he do that was so controversial?
Simple: he changed the rules of the game in the middle of the match.
According to RTW Investments, the FDA denied or discouraged approval applications for at least eight drugs in the past year. The reason? The agency questioned the data companies used to support their applications. So far, that sounds reasonable — after all, the FDA exists to protect us from bad medicine.
The problem is these companies claim they were following prior guidance from the FDA itself about what kind of evidence would be accepted. In other words: the FDA said "you can use this type of proof," the companies spent years and billions developing treatments based on that, and then the FDA turned around and said "changed my mind, this doesn't cut it anymore."
That's the equivalent of building a house following the city's building code, and when you go to get your certificate of occupancy, the inspector tells you the code changed last week and now your house is illegal.
Moderna, for example, had its application for review of its flu shot initially rejected by the FDA — before the agency reversed course. UniQure was discouraged from seeking accelerated approval for an experimental treatment for Huntington's disease. Huntington's, people. A devastating neurodegenerative disease with no cure.
A former FDA official told CNBC, on condition of anonymity, that these reversals represent "the worst kind of regulatory uncertainty" — because companies are told one thing and then experience something completely different.
The FDA defends itself (as always)
An agency spokesperson dropped the usual boilerplate statement: "there is no regulatory uncertainty," the FDA "makes evidence-based decisions," and "doesn't rubber-stamp approvals."
Come on, nobody's asking for a rubber stamp. What the industry is asking for is consistency. Predictability. Rules that don't change depending on who's sitting in the chair.
Nassim Taleb would call this a textbook skin in the game problem: the people making regulatory decisions suffer zero consequences when they change the rules. The ones who suffer are the patients waiting for treatments and the investors who put real money into biotech companies.
The bigger picture
All of this is happening under Robert F. Kennedy Jr.'s leadership at HHS, which has already pushed through staff cuts and a restructuring of the FDA. The atmosphere is one of widespread distrust. The industry fears the agency is strangling the development of new treatments. Critics warn about risks to patient safety.
And the market? The market prices in uncertainty. Biotech stocks already live in a world of insane volatility — where the fate of a billion-dollar company can hinge on a letter from the FDA. When the regulator becomes unpredictable, the risk premium goes up, capital flees, and the one stuck with the bill is the patient who won't get access to the drug that could have been approved.
Prasad heads back to the University of California, San Francisco, where he came from. Makary promises to name a successor before his departure.
The question that remains is brutal and simple: who in the biotech market is going to trust the next person who sits in that chair?
